ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Today's Webinar from the Brain & Behavior Research Foundation - Motivational Modulation of Cognitive Control in ADHD
July 09, 2024 09:41 ET
|
Brain & Behavior Research Foundation
New York, July 09, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Motivational Modulation of Cognitive Control in ADHD” today, July 9, 2024,...
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 09, 2024 07:00 ET
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
July 01, 2024 04:30 ET
|
Nexstim Oyj
Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
June 27, 2024 07:10 ET
|
STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
Global Mental Health Screening Market Size To Worth USD 2.62 Billion By 2033 l CAGR of 11.78%
June 18, 2024 16:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 18, 2024 (GLOBE NEWSWIRE) -- The Global Mental Health Screening Market Size is to Grow from USD 0.86 Billion in 2023 to USD 2.62 Billion by 2033, at a Compound Annual...
Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path to More Personalized Treatments - A Free Webinar from the Brain & Behavior Research Foundation
June 03, 2024 13:19 ET
|
Brain & Behavior Research Foundation
New York, June 03, 2024 (GLOBE NEWSWIRE) -- NEW YORK -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Neurocognitively-Defined Subtypes in Bipolar Disorder: A Path...
Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder - A Free Webinar from the Brain & Behavior Research Foundation
May 07, 2024 11:13 ET
|
Brain & Behavior Research Foundation
New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on...
Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreement
May 07, 2024 08:30 ET
|
Real Brands Inc.
North Providence, RI, May 07, 2024 (GLOBE NEWSWIRE) -- Real Brands Inc. (OTCPK: RLBD) announced today that it has added Richard J. Goldberg, MD, MS, to its Board of Directors, and The Company has...
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
May 03, 2024 11:00 ET
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program